The Medical Letter on Drugs and Therapeutics
Roflumilast (Daliresp) for COPD
July 25, 2011 (Issue: 1369)Roflumilast (Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic...more
5. AWP listings according to Price Alert (July 15, 2011).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.